- GemPharmatech has developed a series of proprietary genetically humanized mouse models targeting immune checkpoint molecules on both BALB/c and C57BL/6 genetic backgrounds. The extracellular regions of the mouse immune checkpoints are replaced with the corresponding human fragments, supporting antibody recognition against human immune checkpoints while ensuring proper intracellular signal transduction through the mouse transmembrane and intracellular portions. These models are suitable for antibody efficacy and safety evaluation including bispecific antibody evaluation for cancer immunotherapy and other applications.
- GemPharmatech has also developed a large portfolio of syngeneic mouse tumor models for custom drug efficacy and pharmacokinetics testing to better serve the needs of cancer researchers. They complement the growing list of humanized immune checkpoint mouse models for anti-cancer immunotherapies R&D. They potentially have higher sensitivity as well as improved temporal resolution of the response.